

Medaysis


OX40/CD134/TNFSF4 [MD102]

OX40, also known as CD134, is a T-cell activation marker and is a member of the tumor necrosis factor (TNF) superfamily of proteins. OX40 is a co-stimulatory receptor that binds to OX40 ligand (OX40L) and initiates cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX40, a cell surface glycoprotein and member of TNF receptor family, is expressed by CD4 T cells and provides a costimulatory signal for T cell activation. Mimicking the natural OX40L, anti-OX40 monoclonal antibody selectively binds to and activates the OX40 receptor. Receptor activation induces proliferation of memory and effector T lymphocytes. In the presence of tumor associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells.

Several immunomodulatory agents that target T-cell coinhibitory receptors, such as PD-1 and CTLA-4, have been developed to boost T-cell-mediated antitumor immune responses to many types of cancer, and immune checkpoint blockade has become a standard first-line treatment in multiple solid cancers, including melanoma, lung cancer, bladder cancer, and kidney cancer. This new clinical paradigm has shifted research efforts in tumor immunology to prioritize the identification of additional immunoregulatory targets and rational combinatorial treatments to further increase the rate of potent and durable antitumor immune responses. TNF members have been recognized as ideal targets to provide costimulatory signals in combination with immune checkpoint blocking antibodies. A triple combination of OX40 with PD-1 and CTLA-4 may help augment the efficacy of dual PD-1/CTLA-4 blockade by enhancing the expansion, survival, and cytolytic activity of tumor-reactive effector T cells. Additionally, combination of anti-OX40 monoclonal antibody treatment plus the HER2 cancer vaccine promoted anti-tumor functions of CD8 T cells and led to tumor regression.

<https://clincancerres.aacrjournals.org/content/25/21/6406>

Cat.No.	Size	Dilution	Claim
MC0405	1ml	50-200	RUO
MC0405RTU7	7ml	Prediluted	RUO



FFPE human RCC